Cardiovascular diseases remain the number one diseases affecting patients' morbidity and mortality. The adenosine receptors are G-protein coupled receptors which have been of interest for drugs target for the treatment of multiple diseases ranging from cardiovascular to neurological. Adenosine receptors have been connected to several biological pathways affecting the physiology and pathology of the cardiovascular system. In this review, we will cover the different adenosine receptor ligands that have been identified to interact with adenosine receptors and affect the vascular system. These ligands will be evaluated from clinical as well as medicinal chemistry perspectives with more emphasis on how structural changes in structure translate into ligand potency and efficacy. Adenosine receptors represent a novel therapeutic target for development of treatment options treating a wide variety of diseases, including vascular disease and obesity.
Introduction
The cardiovascular system plays an important role in the health and well-being of patients. Dysregulation of the cardiovascular system has large implications, for example hypertension can be a major risk factor for the development of stroke and heart disease. It has been found that more than 30% of adults will run the risk of dying from either heart disease or stroke [1] . This has led to an increased search for the understanding of the pathology behind these life-threatening disease states, and is evident in both medical literature as well as in the health care commercial market.
The vascular system plays an important role in the normal physiology, affecting several organ systems, including the brain and renal system. Any pathological changes in this system can lead to chronic disease states, including altering the structure of blood vessels in the kidney and may lead to cerebrovascular diseases such as Alzheimer's disease. In the clinical setting, patients who are being treated for cardiovascular diseases, easily experience polypharmacy as the normal treatment paradigm. Although several classical drug targets exist in the treatment of the cardiovascular system, e.g., beta-antagonists, voltage gated calcium blockers (VGCC) etc., a deeper knowledge is needed to functionally treat this system to achieve the maximal decrease in mortality and morbidity. One of the newer drug targets which we are investigating is the adenosine receptor signaling cascade and its effect on cardiovascular physiology.
Role of Adenosine in Cardiovascular Function
Adenosine is a purine nucleoside which plays an important physiological role due to the presence of the adenosine receptors in practically every tissue type [2, 3] . There are four distinct adenosine 
Medicinal Chemistry
The adenosine receptor family has been targeted by several groups to discover novel compounds which can modulate the function of these receptors [5, 25] . One major breakthrough in this field was the crystallization of the adenosine A2A receptor by the group of Jaakola et al. [26] . Table 1 shows the different adenosine receptors which have been crystallized and the protein data bank access codes (PDB). GPCRs and transmembrane receptors were notoriously difficult to crystallize before the adenosine A2A receptor crystal was solved. The subtype selective antagonist ZM241385 was co-crystalized and was shown to bind in a manner which changed the interaction between the helical loops and the internal core of the protein (PDB file 3EML). Of note with GPCRs is the extracellular loops (ECL), which have been shown to play an important role in the GPCR function, with noted specific structural changes with agonist and antagonist interactions. Table 1 shows the deposited Protein Data Bank codes for the selected different crystal structures of the adenosine A2A receptor, as well as adenosine A1 receptor. Recently, the adenosine A1 receptor was crystallized by the group of Glukhova et al. [27] and revealed an interesting difference in the binding pocket between the adenosine A2A and A1 receptors. A few noticeable differences include the ECL, which was significantly different in the adenosine A1 receptor, and the presence of a wider extracellular binding cavity for ligands. Additionally, a secondary binding pocket of the primary binding pocket of adenosine A1 receptor was found, when compared to the A2A receptor (Figures 2 and 3 ). Adenosine receptors play an important role in the physiology of the cardiovascular system. For instance, in coronary smooth muscle cells (CSMC), the activation of adenosine A 1 receptors can be protective against ischemic events in cell culture. The stimulation of the adenosine A 1 receptor in these cells was found to upregulate iNOS, HSP27, as well as PKC-epsilon signaling in the CSMC. Additional studies indicated that the activation of the adenosine A 1 receptors stimulate the PKC kinases alpha, beta, gamma, epsilon and zeta, but not delta and mu. Overexpression of adenosine A 1 receptors was shown to offer protection against ischemic stress, primarily via the iNOS and K ATP channel interaction [13] [14] [15] [16] .
Adenosine A 2A receptors play a role in vascular tone where they cause vasodilation. This vasodilatation activity is thought to be mediated by the cytochrome P-450 cyp epoxygenases, and that the knockout of the adenosine A 2A receptor leads to vasoconstriction via the CYP4a cytochrome P-450 system. Further studies showed that the role adenosine A 2A receptor plays in vasodilation is thought to help in the avoidance of salt sensitivity, and that under high salt conditions, adenosine A 2A receptor leads to increased expression of the CYP2C29 epoxygenases. The effect of high salt concentrations in the diet leads to increase in blood pressure. In mice fed a high-salt diet, there was an increased expression of A 2A receptors and CYP2J2, whereas the expression of soluble epoxide hydrolase (sEH), CYP4a, and adenosine A 1 receptors was decreased. The latter signaling of adenosine A 1 receptor causes vasoconstriction in the normal-salt diet. The vasodilation by adenosine A 2A receptors via the CYP epoxygenases was shown to persist in mice where endothelium NOS (eNOS) was knocked out, and the adenosine A 1 receptor-induced vasoconstriction via sEH and CYP4A was persistent, indicating the constitutive pathway is not dependent on the NO signaling [17] [18] [19] [20] .
The role of adenosine A 2A receptors in the vasodilation activity was shown to be linked to the MAP-kinases In mice, where the adenosine A 2A receptor was knocked out, mice showed increased contraction when exposed to adenosine The increased vasoconstriction was thought to occur via an upregulation of adenosine A 1 receptors and CYP4a can lead to upregulation of PKC-alpha which can activate the PKC-alpha-ERK1/2 pathway [20, 21] . Additionally, the adenosine A 2A -mediated vasodilation was found to relate to soluble expoxide hydrolase (sEH). In sEH-knockout mice, the mice showed an increase in adenosine A 2A receptor expression, as well as CYP2J and PPAR-gamma, whereas the adenosine A 1 receptor was decreased, along with PPAR-alpha [22, 23] . The high-salt diet can augment the vascular contraction in adenosine A 2A -knockout mice, due to the increased adenosine A 1 receptor levels. Normally adenosine A 2A receptor shows enhanced vasodilation in a high-salt diet due to increased cyp-expoxygenases-derived epoxyeicosatrienoic acids (EETs) in the vascular system [23] , as well as PPAR-gamma and K ATP channels [24] , PPAR-gamma, and K ATP channels. Furthermore, in sEH-overexpressed mice, adenosine A 1 receptor levels are increased, vascular tone is increased, and K ATP channel-mediated relaxation is decreased [24] . Figure 1 summarizes the role adenosine receptors play in the vascular tone.
The adenosine receptor family has been targeted by several groups to discover novel compounds which can modulate the function of these receptors [5, 25] . One major breakthrough in this field was the crystallization of the adenosine A 2A receptor by the group of Jaakola et al. [26] . Table 1 shows the different adenosine receptors which have been crystallized and the protein data bank access codes (PDB). GPCRs and transmembrane receptors were notoriously difficult to crystallize before the adenosine A 2A receptor crystal was solved. The subtype selective antagonist ZM241385 was co-crystalized and was shown to bind in a manner which changed the interaction between the helical loops and the internal core of the protein (PDB file 3EML). Of note with GPCRs is the extracellular loops (ECL), which have been shown to play an important role in the GPCR function, with noted specific structural changes with agonist and antagonist interactions. Table 1 shows the deposited Protein Data Bank codes for the selected different crystal structures of the adenosine A 2A receptor, as well as adenosine A 1 receptor. Recently, the adenosine A 1 receptor was crystallized by the group of Glukhova et al. [27] and revealed an interesting difference in the binding pocket between the adenosine A 2A and A 1 receptors. A few noticeable differences include the ECL, which was significantly different in the adenosine A 1 receptor, and the presence of a wider extracellular binding cavity for ligands. Additionally, a secondary binding pocket of the primary binding pocket of adenosine A 1 receptor was found, when compared to the A 2A receptor (Figures 2 and 3 ). Table 1 . Crystal structures of the adenosine receptors which can be used for drug discovery projects. For adenosine A3 receptor, citations for the homology models are shown, but to this date there has not been a crystal structure solved for this isoform. For instance, the group of Almerico et al. [28] used adenosine A2A receptor structure in conjunction with homology modeling to develop a homology model of adenosine A3 receptor. This model was then used to mine the ZINC database for novel adenosine A3 receptor ligands, using a combination of docking and quantitative structureactivity relationships (QSAR) techniques.
The adenosine receptor has been targeted in the past few years for therapeutic drug development, as can be seen by the number of clinical trials featuring these ligands. Figure 4 shows several of the compounds which have been evaluated. The reader is referred to an excellent review on the clinical trials of these compounds [3] . The therapeutic areas targeted by these clinical trials range from cardiovascular to neurodegenerative diseases, such as Parkinson's disease. For instance, for several years the adenosine A2A receptor antagonist istradefylline (KW-6002, a styrylxanthine) has been evaluated for clinical efficacy in Parkinson's disease. Although istradefylline did not get approval by For adenosine A3 receptor, citations for the homology models are shown, but to this date there has not been a crystal structure solved for this isoform. For instance, the group of Almerico et al. [28] used adenosine A2A receptor structure in conjunction with homology modeling to develop a homology model of adenosine A3 receptor. This model was then used to mine the ZINC database for novel adenosine A3 receptor ligands, using a combination of docking and quantitative structureactivity relationships (QSAR) techniques.
The adenosine receptor has been targeted in the past few years for therapeutic drug development, as can be seen by the number of clinical trials featuring these ligands. Figure 4 shows several of the compounds which have been evaluated. The reader is referred to an excellent review on the clinical trials of these compounds [3] . The therapeutic areas targeted by these clinical trials range from cardiovascular to neurodegenerative diseases, such as Parkinson's disease. For instance, for several years the adenosine A2A receptor antagonist istradefylline (KW-6002, a styrylxanthine) has been evaluated for clinical efficacy in Parkinson's disease. Although istradefylline did not get approval by For adenosine A 3 receptor, citations for the homology models are shown, but to this date there has not been a crystal structure solved for this isoform. For instance, the group of Almerico et al. [28] used adenosine A 2A receptor structure in conjunction with homology modeling to develop a homology model of adenosine A 3 receptor. This model was then used to mine the ZINC database for novel adenosine A 3 receptor ligands, using a combination of docking and quantitative structure-activity relationships (QSAR) techniques.
The adenosine receptor has been targeted in the past few years for therapeutic drug development, as can be seen by the number of clinical trials featuring these ligands. Figure 4 shows several of the compounds which have been evaluated. The reader is referred to an excellent review on the clinical trials of these compounds [3] . The therapeutic areas targeted by these clinical trials range from cardiovascular to neurodegenerative diseases, such as Parkinson's disease. For instance, for several years the adenosine A 2A receptor antagonist istradefylline (KW-6002, a styrylxanthine) has been evaluated for clinical efficacy in Parkinson's disease. Although istradefylline did not get approval by the USA FDA, it was recently approved for use in Japan for the use in patients [29] . Adenosine has been on the market for a few years in an injectable form e.g., Teva's Adenoscan ® , while caffeine is available in several generic forms to treat sleep apnea of prematurity in infants.
Molecules 2017, 21, 917 5 of 11 the USA FDA, it was recently approved for use in Japan for the use in patients [29] . Adenosine has been on the market for a few years in an injectable form e.g., Teva's Adenoscan ® , while caffeine is available in several generic forms to treat sleep apnea of prematurity in infants. The medicinal chemistry surrounding the development of novel adenosine receptor ligands was largely driven in the beginning by derivatization of the adenosine scaffold to gain understanding of the structure-activity relationships especially between adenosine A1 and A2A receptors. From these studies, novel scaffolds were developed, such as the core styrylxanthine from which istradyfilline (KW-6002) was derived ( Figure 5 ). [25] . For a more in-depth review, the reader is referred to a recent review [3] . [25] . For a more in-depth review, the reader is referred to a recent review [3] .
The medicinal chemistry surrounding the development of novel adenosine receptor ligands was largely driven in the beginning by derivatization of the adenosine scaffold to gain understanding of the structure-activity relationships especially between adenosine A 1 and A 2A receptors. From these studies, novel scaffolds were developed, such as the core styrylxanthine from which istradyfilline (KW-6002) was derived ( Figure 5 ). Compounds such as the 8-styrylxanthines, of which istradyfilline is a member, can easily be prepared by the acylation of a diaminouracil and a trans-cinnamic acid ( Figure 6 ) [30] . Compounds such as the 8-styrylxanthines, of which istradyfilline is a member, can easily be prepared by the acylation of a diaminouracil and a trans-cinnamic acid ( Figure 6 ) [30] . Compounds such as the 8-styrylxanthines, of which istradyfilline is a member, can easily be prepared by the acylation of a diaminouracil and a trans-cinnamic acid ( Figure 6 ) [30] . Compounds such as the 8-styrylxanthines, of which istradyfilline is a member, can easily be prepared by the acylation of a diaminouracil and a trans-cinnamic acid ( Figure 6 ) [30] . Further studies also showed that the xanthine moiety can be replaced and still retains adenosine receptor activity [32] . The group of Van der Walt et al., synthesized a series of sulfanylphthalimide analogues and tested them for adenosine A 1 and A 2A receptor affinity. The phthalimide moiety has been found in other drug-like compounds, such as thalidomide or pomidomide. The results showed that the compounds were selective for adenosine A 1 over A 2A receptor, and that the most potent compound was 5-[(4-methoxybenzyl) sulfanyl]phthalimide with a KI of 369 nM. Similarly, the 5-benzylopxyphatalimide and 5-benzyloxyistatin were inactive against the A 2A receptor, and the affinity for A 1 was lower (Ki~5 µM) than for the sulfanyl-derivatives (Figure 8 ).
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Carbamate-pyrimidines were prepared to evaluate their binding to the adenosine A1 over A2A receptors due to the carbamate moiety featuring in several drug-types. The group of Robinson et al., prepared a set of carbamate compounds and found that 3-(2-amino-6-phenylpyrimidin-4-yl)phenyl morpholine-4-carboxylate compound was the most potent compound with an Ki of 2.65 nM for adenosine A1 receptor and an Ki of 3.50 nM for the adenosine A2A receptor ( Figure 10 ) [34] . This compound was also able to reverse catalepsy in rats when dosed at 0.4 mg/kg, suggesting effective in vivo therapeutic potential. Since previous studies have suggested that the styrylxanthine can be used to develop dual adenosine A1 and A2A receptor ligands, the group of Harmse et al., synthesized a series of parasubstituted 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine analogs [35] . They found that para substitution on the phenoxymethyl side chain increased the affinity for the adenosine A2A receptor, with methoxy (OCH3) being the most potent with a Ki of 237 nM (Figure 11 ). Additionally, it was found that this compound behaved as an antagonist when screened in the GTP-shift assay using rat brain membranes. Figure 12 shows a SAR synopsis from the studies of the phenoxymethyl replacement of the styryl moiety. We employed docking studies to investigate the differences between the two compounds in their affinity for the adenosine A2A receptor (Figure 13 ), using MOE 2016 [36] . We found that both compounds orient with the xanthine pointed to the outside of the pocket, and the side chain oriented inwards. A crystal water molecule seems to be bridging the compounds with hydrogen bonds and allows for interaction with the protein. Since previous studies have suggested that the styrylxanthine can be used to develop dual adenosine A 1 and A 2A receptor ligands, the group of Harmse et al., synthesized a series of para-substituted 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine analogs [35] . They found that para substitution on the phenoxymethyl side chain increased the affinity for the adenosine A 2A receptor, with methoxy (OCH3) being the most potent with a Ki of 237 nM (Figure 11 ). Carbamate-pyrimidines were prepared to evaluate their binding to the adenosine A1 over A2A receptors due to the carbamate moiety featuring in several drug-types. The group of Robinson et al., prepared a set of carbamate compounds and found that 3-(2-amino-6-phenylpyrimidin-4-yl)phenyl morpholine-4-carboxylate compound was the most potent compound with an Ki of 2.65 nM for adenosine A1 receptor and an Ki of 3.50 nM for the adenosine A2A receptor ( Figure 10) [34]. This compound was also able to reverse catalepsy in rats when dosed at 0.4 mg/kg, suggesting effective in vivo therapeutic potential. Since previous studies have suggested that the styrylxanthine can be used to develop dual adenosine A1 and A2A receptor ligands, the group of Harmse et al., synthesized a series of parasubstituted 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine analogs [35] . They found that para substitution on the phenoxymethyl side chain increased the affinity for the adenosine A2A receptor, with methoxy (OCH3) being the most potent with a Ki of 237 nM (Figure 11 ). Additionally, it was found that this compound behaved as an antagonist when screened in the GTP-shift assay using rat brain membranes. Figure 12 shows a SAR synopsis from the studies of the phenoxymethyl replacement of the styryl moiety. We employed docking studies to investigate the differences between the two compounds in their affinity for the adenosine A2A receptor (Figure 13 ), using MOE 2016 [36] . We found that both compounds orient with the xanthine pointed to the outside of the pocket, and the side chain oriented inwards. A crystal water molecule seems to be bridging the compounds with hydrogen bonds and allows for interaction with the protein. Additionally, it was found that this compound behaved as an antagonist when screened in the GTP-shift assay using rat brain membranes. Figure 12 shows a SAR synopsis from the studies of the phenoxymethyl replacement of the styryl moiety. We employed docking studies to investigate the differences between the two compounds in their affinity for the adenosine A 2A receptor (Figure 13 ), using MOE 2016 [36] . We found that both compounds orient with the xanthine pointed to the outside of the pocket, and the side chain oriented inwards. A crystal water molecule seems to be bridging the compounds with hydrogen bonds and allows for interaction with the protein. 
Conclusions
The adenosine receptor system plays an important physiological role in the cardiovascular response. Considering the signaling role they play, these receptors represent a novel class of drug targets which can have phenotypic and therapeutic potential to treat people with high blood pressure and related cardiovascular disorders. As we gain understanding in the mechanism of action of these receptors, we will undoubtedly be able to develop effective adenosine ligands for use in cardiovascular diseases. 
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